2Vanholder R, Meert N, Schepers E, et al. Uremic toxins: do we know e- nough to explain Uremic[J]? Blood Purif,2008,26( 1 ):77- 81. 被引量：1
3Mostovaya IM, Blankestijn PJ, Bots ML, et al. Cinlcal evidence on hemodiafiltration: a systematic review and a meta-analysis[ J]. Semin Dial, 2014,27(2) : 119 - 127. 被引量：1
4Vlassara FI, Brownlee M, Cerami A. Accumulation of diabetic rat periph- eral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts[ J]. J Exp Med, 1984,160( 1 ) : 197 - 207. 被引量：1
5Meerwaldt R, Zeebregts CJ, Navis G, et al. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialy- sis[J]. Am J Kidney Dis,2009,53(1) : 138 - 150. 被引量：1
6Tessitore N, Lapolla A, Arico CN, et al. Hemodialysis techniques and ad- vanced glycation end products[J]. Contrib Nephrol,2001,131:33- 39. 被引量：1
7Furuya R, Kumagai H, Odamaki M, et al. Impact of residual renal func- tion on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients[J]. Nephron Clin Pract,2009,112(4) : c255 - 261. 被引量：1
8Glenn JV, Stitt AW. The role of advanced glycation end products in reti- nal ageing and disease [ J ]. Biochim Biophys Acta, 2009, 1790 (10) : 1109 - 1116. 被引量：1
9Stitt AW, Jenkins A J, Cooper ME. Advanced glycation end products anddiabetic complications [ J ]. Expert Opin Investig Drugs, 2002,11 (9) : 1205 - 1223. 被引量：1
10Furuya R, Kumagai H, Miyata T, et al. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients[J]. Clin Exp Nephrol,2012,16(3) :421 - 426. 被引量：1
